Praxis Precision Medicines, Inc. PRAX
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -2.99%
- 1 year
- +42.25%
- Open
- 283.92
- Prev close
- 288.62
- Mkt cap
- 7.98B
- Vol
- 306.56K
- Avg vol
- 461.47K
- EPS
- -12.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 280.00
- High
- 290.06
- Forward P/E
- -30.09
- Beta
- 2.81
- Short ratio
- 7.11
- Inst. own
- 123.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 302.86
- 200-d avg
- 314.90
- 1y target
- 650.00
2Y chart
Events in this range
- Aug 4, 2025Earnings: -3.31; estimate -3.4; surprise 2.65%
- Nov 5, 2025Earnings: -3.36; estimate -3.45; surprise 2.61%
- Feb 19, 2026Earnings: -3.5; estimate -3.12593; surprise -11.97%
- May 7, 2026Earnings: -3.2; estimate -3.58; surprise 10.61%
- Aug 6, 2026Earnings: -2.87; estimate -3.67; surprise 21.8%
- Sep 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 6, 2026Rating: BTIG · Buy → Buy
- Oct 6, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 15, 2026Rating: UBS · — → Buy
- Oct 16, 2026Rating: JP Morgan · — → Overweight
Signals (81)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| RSI: Oversold | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 13, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 22, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 20, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 31, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 30, 2025 | 10 months ago |
| RSI: Overbought | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 24, 2025 | 10 months ago |
| RSI: Overbought | Dec 22, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| RSI: Overbought | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 4, 2025 | 12 months ago |
| RSI: Overbought | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| RSI: Oversold | Sep 12, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| RSI: Overbought | Jul 21, 2025 | 1 year ago |
| RSI: Overbought | Jul 16, 2025 | 1 year ago |
| RSI: Overbought | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| MACD: Buy Signal | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| SMA: Bullish | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| RSI: Oversold | Mar 18, 2025 | 1 year ago |
| RSI: Oversold | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 21, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 19, 2025 | 1 year ago |
| SMA: Bullish | Jan 28, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 22, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 20, 2024 | 1 year ago |
Key statistics
- Market cap
- 7.98B
- Enterprise value
- 7.30B
- Trailing P/E
- 0.00
- Forward P/E
- -30.09
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.95
- EPS (TTM)
- -12.95
- Beta
- 2.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -199.44M
- Total cash
- 758.55M
- Total debt
- 1.09M
- Return on equity
- -38.86%
- Shares outstanding
- 27.92M
- Short % of float
- 14.08%
- 50-day average
- 302.86
- 200-day average
- 314.90
Analyst view
Consensus: strong buy
- Target (low)
- 188.00
- Target (mean)
- 650.00
- Target (high)
- 1,201.00
- Strong buy4
- Buy15
- Hold1
- Sell1
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -3.63.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -3.54 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -3.67 | -2.87 | +0.80 | +21.80% |
| May 7, 2026 | Mar 31, 2026 | -3.58 | -3.20 | +0.38 | +10.61% |
| Feb 19, 2026 | Dec 31, 2025 | -3.13 | -3.50 | -0.37 | -11.97% |
| Nov 5, 2025 | Sep 30, 2025 | -3.45 | -3.36 | +0.09 | +2.61% |
| Aug 4, 2025 | Jun 30, 2025 | -3.40 | -3.31 | +0.09 | +2.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | JP Morgan | init | — | Overweight |
| Oct 15, 2026 | UBS | init | — | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 6, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 6, 2026 | BTIG | main | Buy | Buy |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- praxismedicines.com
News
- Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
- JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700
- HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
- HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
- BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826
- Praxis Precision Medicine Q2 2026 Earnings Call Transcript
- HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
- Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target
- Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
- RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
Your note
Sign in to keep a note on PRAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAGE CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 15, 2025 | 0 |
| ARBUCKLE STUART A | Director | Stock Award(Grant) | Jun 9, 2026 | 2,537 |
| KELLY TIMOTHY EDWIN | Chief Financial Officer | Stock Award(Grant) | May 13, 2026 | 31,167 |
| KINDLER JEFFREY B | Director | Stock Award(Grant) | Jun 9, 2026 | 2,537 |
| MASTROCOLA LAUREN | Officer | Stock Award(Grant) | May 13, 2026 | 13,572 |
| MITCHELL DEAN J | Director | Stock Award(Grant) | Jun 9, 2026 | 18,622 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jupiter Topco LLC | 12.25% | 3,421,374 | 978.27M | Jun 29, 2026 |
| FMR, LLC | 8.30% | 2,316,907 | 662.47M | Jun 29, 2026 |
| Blackrock Inc. | 8.21% | 2,292,585 | 655.52M | Jun 29, 2026 |
| Perceptive Advisors Llc | 7.29% | 2,035,986 | 582.15M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 6.28% | 1,753,198 | 501.29M | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 5.48% | 1,529,788 | 437.41M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 885,411 | 253.17M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.33% | 650,750 | 186.07M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 639,578 | 182.87M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.53% | 427,949 | 122.36M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.47% | 411,429 | 117.64M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 405,016 | 115.81M | Jun 29, 2026 |